ArriVent BioPharma (AVBP)
ArriVent BioPharma (AVBP) stock research: performance, analysts' price targets, earnings, revenue and margins, technicals and insider trades.
- AVBP last traded at $10.52 on 2026-11-20, -6.57% for the session.
- ArriVent BioPharma: market cap $544.13M.
- Over the past year AVBP returned -47.48%, with a year-to-date return of -47.71%.
Trial setback weighs on ArriVent shares
ArriVent shares slipped 0.6% today while the S&P 500 and Nasdaq 100 advanced. The recent focus remains on a failed lung cancer trial, even as the company reports progress in other drug studies and continues enrollment in a pivotal trial.
Published 2026-11-19 15:01:38 UTC.